|
gptkbp:instance_of
|
gptkb:patches
|
|
gptkbp:administered_by
|
applying to the skin
|
|
gptkbp:application
|
hip
|
|
gptkbp:approves
|
gptkb:2006
gptkb:FDA
|
|
gptkbp:available_in
|
different dosages
|
|
gptkbp:brand
|
gptkb:Daytrana
|
|
gptkbp:clinical_trial
|
studies on pediatric use
studies on efficacy
studies on safety
studies on pharmacokinetics
studies on long-term use
|
|
gptkbp:clinical_use
|
enhances focus
improves attention
reduces hyperactivity
|
|
gptkbp:contains
|
gptkb:Sannin
|
|
gptkbp:contraindication
|
gptkb:Ophthalmology
heart problems
history of substance abuse
|
|
gptkbp:duration
|
up to 9 hours
|
|
gptkbp:formulation
|
matrix patch
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Daytrana patch
|
|
gptkbp:interacts_with
|
antidepressants
MAO inhibitors
antihypertensives
|
|
gptkbp:is_involved_in
|
ADHD patients
|
|
gptkbp:is_monitored_by
|
gptkb:weight
blood pressure
heart rate
|
|
gptkbp:manufacturer
|
gptkb:Shire_Pharmaceuticals
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:method_of_action
|
CNS stimulant
|
|
gptkbp:packaging
|
single-use pouches
|
|
gptkbp:patient_education
|
potential side effects
how to apply the patch
how to remove the patch
importance of adherence to prescribed regimen
what to do if a dose is missed
|
|
gptkbp:patient_population
|
children and adolescents
|
|
gptkbp:regulatory_compliance
|
prescription only
|
|
gptkbp:releases_medication
|
through the skin
|
|
gptkbp:removal_time
|
after 9 hours
|
|
gptkbp:service_frequency
|
once daily
|
|
gptkbp:shelf_life
|
up to 24 months
|
|
gptkbp:side_effect
|
anxiety
nausea
decreased appetite
insomnia
dry mouth
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:submission_deadline
|
morning
|
|
gptkbp:used_for
|
treatment of ADHD
|
|
gptkbp:bfsParent
|
gptkb:Sannin
|
|
gptkbp:bfsLayer
|
5
|